premıum anabolıcs for professıonals!

Retatrutide 10mg Pharma Quality - Triple Effect

10% Discount code: BTC10 (for BTC Payments ONLY)

$112.00$86.00

The "Triple G" Agonist

Retatrutide (LY3437943) is an investigational peptide hormone currently being developed for the treatment of obesity and Type 2 diabetes. Unlike earlier generations of weight-loss drugs, Retatrutide is a triple hormone receptor agonist.

How It Works

Retatrutide is often referred to as a "GGG" agonist because it mimics three distinct hormones, offering a synergistic effect on metabolism and fat burning:

  1. GLP-1 (Glucagon-like peptide-1): Regulates appetite and insulin secretion (similar to Semaglutide).

  2. GIP (Glucose-dependent insulinotropic polypeptide): Helps regulate blood sugar and fat accumulation (similar to Tirzepatide).

  3. Glucagon: This is the key differentiator. It activates the glucagon receptor in the liver to increase energy expenditure and burn fat, essentially speeding up the metabolism.

Current Status

  • Approval Status: Retatrutide is currently in Phase 3 clinical trials. It has not yet been approved by the FDA or EMA.

  • Potential Impact: Early Phase 2 data suggested significantly higher weight loss percentages (up to 24% in 48 weeks) compared to currently approved medications.

Dosage Protocols (Based on Clinical Trials)

Since Retatrutide is not yet commercially available, there is no official FDA-approved labeling. The following dosages are based on the protocols used in the Phase 2 obesity clinical trials (published in the New England Journal of Medicine).

The medication is administered via a weekly subcutaneous injection.

Titration Strategy

Similar to other GLP-1 drugs, Retatrutide requires a slow escalation to mitigate heart rate increases and gastrointestinal issues.

  • Starting Dose: Typically 2 mg or 4 mg once weekly.

  • Escalation: The dose is usually increased every 4 weeks.

  • Target Maintenance Doses: Clinical trials tested maintenance doses of 4 mg, 8 mg, and 12 mg.

    • The 8 mg and 12 mg doses showed the highest efficacy in weight reduction.

Example Clinical Trial Schedule:

  • Weeks 1-4: 2 mg

  • Weeks 5-8: 4 mg

  • Weeks 9-12: 8 mg (potential maintenance)

  • Weeks 13+: 12 mg (maximum tested maintenance dose)

Important Safety Note

Warning: Retatrutide is an investigational drug. The long-term safety profile, particularly concerning heart rate elevation and liver impact, is still being studied. The dosages mentioned above are experimental and sourced from research studies, not medical prescriptions.